You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

380 Results
Cancer facts
Jun 2019
Guidelines and Advice
Status: In-Review
ID: GL 2-24
May 2019
Drug
Other Name(s): Folotyn®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2021
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ribociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant according to clinical criteria
ODB - General Benefit
    fulvestrant
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ribociclib ,
fulvestrant
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2021
Regimen
Cancer Type:
Hematologic, 
Rare Diseases, 
Sarcoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
prednisone,
DOXOrubicin,
vinCRIStine,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2019
Guidelines and Advice
Status: Current
ID: GL 12-10
Version: 2
Jul 2019
Guidelines and Advice
Status: Current
ID: PET 2018-2
Jul 2019
Guidelines and Advice
Status: Current
Version: 1
Aug 2019
Guidelines and Advice
Status: Current
Version: N/A
Aug 2019
Guidelines and Advice
Status: Current
ID: GL 3-20
Version: N/A
Aug 2019
Guidelines and Advice
Status: Current
Version: 1
Aug 2019
Guidelines and Advice
Status: Current
ID: 21-4
Version: N/A
Aug 2019

Pages